| Q57057499 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines |
| Q38853230 | 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. |
| Q37158620 | A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients |
| Q52650702 | Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction. |
| Q27025860 | Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? |
| Q92514351 | Advanced Imaging Modalities to Monitor for Cardiotoxicity |
| Q57301157 | Advanced imaging modalities to detect cardiotoxicity |
| Q38747992 | Alternative Biomarkers for Combined Biology |
| Q34650059 | An update on cardio-oncology |
| Q33658456 | Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care |
| Q38727423 | Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker? |
| Q38542462 | Anthracycline-Induced Cardiomyopathy in Adults |
| Q86870023 | Anthracycline-induced cardiomyopathy: The search continues |
| Q38205702 | Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment |
| Q33562971 | Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. |
| Q92073283 | Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy |
| Q47417995 | Assessment of cardiac allograft systolic function by global longitudinal strain: From donor to recipient |
| Q38773470 | Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity |
| Q52808495 | Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. |
| Q40006876 | Automated Functional Imaging by 2D Speckle Tracking Echocardiography Reveals High Incidence of Abnormal Longitudinal Strain in a Cohort of Pediatric Oncology Patients |
| Q90706016 | BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer |
| Q37311943 | Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials |
| Q88868148 | Biomarker Discovery in Cardio-Oncology |
| Q61454620 | Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity |
| Q47703138 | Biomarkers in cancer therapy related cardiac dysfunction (CTRCD). |
| Q93121266 | Can post-chemotherapy cardiotoxicity be detected in long-term survivors of breast cancer via comprehensive 3D left-ventricular contractility (strain) analysis? |
| Q48495062 | Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation? |
| Q36451899 | Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging |
| Q92433295 | Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician |
| Q88711817 | Cancer and Heart Failure: Understanding the Intersection |
| Q34474264 | Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab |
| Q26991674 | Cancer therapy-induced cardiotoxicity: role of ultrasound deformation imaging as an aid to early diagnosis |
| Q42547157 | Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities |
| Q38735433 | Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions |
| Q38791220 | Cardiac Complications of HER2-Targeted Therapies in Breast Cancer |
| Q38632789 | Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity |
| Q36788268 | Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer |
| Q51739297 | Cardiac complications of chemotherapy: role of biomarkers. |
| Q30415201 | Cardiac complications of chemotherapy: role of imaging |
| Q54447524 | Cardiac dysfunction in cancer survivors unmasked during exercise. |
| Q37598919 | Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study |
| Q28081385 | Cardiac risk in the treatment of breast cancer: assessment and management |
| Q38091377 | Cardiac toxicity of anticancer agents |
| Q26741182 | Cardiac toxicity of trastuzumab in elderly patients with breast cancer |
| Q33582865 | Cardiac troponin I is abnormally expressed in non-small cell lung cancer tissues and human cancer cells |
| Q38416816 | Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity |
| Q57495835 | Cardio-oncology: A Focus on Cardiotoxicity |
| Q26750878 | Cardio-oncology: Concepts and practice |
| Q38657849 | Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts |
| Q38665281 | Cardio-oncology: cardiovascular complications of cancer therapy |
| Q61805959 | Cardio-oncology: management of cardiovascular toxicity |
| Q57108766 | Cardio-oncology: protecting the heart from curative breast cancer treatment |
| Q39185620 | Cardio-oncology: the Nuclear Option |
| Q38904284 | Cardiomyopathic Toxicity From Chemotherapy: Is There an Opportunity for Preemptive Intervention? |
| Q38242641 | Cardiomyopathy associated with cancer therapy |
| Q42373758 | Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. |
| Q38508938 | Cardiotoxicity due to Chemotherapy: the Role of Biomarkers |
| Q38343043 | Cardiotoxicity due to chemotherapy: role of cardiac imaging. |
| Q91650757 | Cardiotoxicity of Anthracyclines |
| Q26766063 | Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management |
| Q41704131 | Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment |
| Q36676062 | Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy |
| Q38371293 | Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients |
| Q45073135 | Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. |
| Q50045986 | Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. |
| Q26864094 | Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level |
| Q39103481 | Cardiovascular disease in cancer survivors |
| Q37624268 | Cardiovascular disease in survivors of hematopoietic cell transplantation. |
| Q61454621 | Cardiovascular imaging in cardio-oncology |
| Q38338228 | Cardiovascular prevention in the cancer survivor |
| Q92776949 | Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction |
| Q90415345 | Chemotherapy Related Severe Cardiac Dysfunction - Case Report |
| Q38580452 | Chemotherapy-induced cardiomyopathy |
| Q92218673 | Chemotherapy-related Cardiomyopathy |
| Q35962903 | Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study |
| Q33741091 | Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist. |
| Q37041145 | Contemporary strategies in the diagnosis and management of heart failure |
| Q38543409 | Continued value of adjuvant anthracyclines as treatment for early breast cancer. |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q38559474 | Current and emerging modalities for detection of cardiotoxicity in cardio-oncology |
| Q38845535 | Current views on anthracycline cardiotoxicity. |
| Q90478154 | Detection of radiation induced cardiotoxicity: Role of echocardiography and biomarkers |
| Q53075042 | Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography. |
| Q33565936 | Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction |
| Q38368230 | EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology |
| Q64074097 | Early Detection and Monitoring of Cancer Chemotherapy-Related Left Ventricular Dysfunction by Imaging Methods |
| Q46904082 | Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective |
| Q36365075 | Early detection of cardiotoxicity by 2D and 3D deformation imaging in patients receiving chemotherapy |
| Q34855776 | Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab |
| Q45084464 | Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines |
| Q48503621 | Echocardiography Core Laboratory Reproducibility of Cardiac Safety Assessments in Cardio-Oncology. |
| Q42386926 | Echocardiography for Evaluation of Oncology Therapy-Related Cardiotoxicity |
| Q30427029 | Effects of subacute dietary salt intake and acute volume expansion on diastolic function in young normotensive individuals. |
| Q47131512 | Effects of treatment with chemotherapy and/or tamoxifen on the biomarkers of cardiac injury and oxidative stress in women with breast cancer |
| Q26998273 | Evaluation and management of patients with heart disease and cancer: cardio-oncology |
| Q38855062 | Evaluation of myocardial deformation in patients with Kawasaki disease using speckle-tracking echocardiography during mid-term follow-up. |
| Q26785410 | Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors |
| Q38121064 | Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography |
| Q30401812 | Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging |
| Q38842771 | From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. |
| Q90741833 | Fully automated and comprehensive MRI-based left-ventricular contractility analysis in post-chemotherapy breast cancer patients |
| Q93106057 | Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy |
| Q26797138 | Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer Therapy |
| Q89580190 | Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis |
| Q54535935 | Global longitudinal strain: mature for early detection of anthracyclines-induced cardiotoxicity? |
| Q42406335 | Heart failure and breast cancer therapies: moving towards personalized risk assessment |
| Q38559133 | Heart failure and chemotherapeutic agents |
| Q38868285 | High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury |
| Q48244270 | High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. |
| Q34438850 | High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy |
| Q38171887 | How to monitor cardiac toxicity of chemotherapy: time is muscle! |
| Q38551772 | Identifying cancer patients at risk for cardiotoxicity |
| Q38197733 | Imaging methods for detection of chemotherapy-associated cardiotoxicity and dysfunction |
| Q38978030 | Improving prediction of cardiovascular complications of cancer therapy: what does the future hold? |
| Q36746331 | Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies |
| Q91340471 | Integration of cardiac energetics, function and histology from isolated rat hearts perfused with doxorubicin and doxorubicin-ol; a model for use in drug safety evaluations |
| Q47816202 | Integrin-linked kinase mediates force transduction in cardiomyocytes by modulating SERCA2a/PLN function |
| Q40809782 | Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. |
| Q88008688 | Left Ventricular Dysfunction and Chemotherapeutic Agents |
| Q55026521 | Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction. |
| Q60922429 | Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy |
| Q88143157 | Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity |
| Q89707927 | Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis |
| Q50527749 | Long-term systolic function in children and young adults after hematopoietic stem cell transplant. |
| Q36339976 | Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab |
| Q91961812 | Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients |
| Q38192517 | Making sense of high sensitivity troponin assays and their role in clinical care |
| Q39826550 | Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis |
| Q48316178 | Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. |
| Q91159387 | Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years |
| Q90178681 | NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab |
| Q27022965 | Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines |
| Q39005990 | New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. |
| Q40796619 | Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction |
| Q27024715 | Noninvasive imaging of cardiovascular injury related to the treatment of cancer |
| Q38936473 | Novel applications of proton therapy in breast carcinoma |
| Q30487537 | Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine |
| Q38982311 | Optimizing cardio-oncology programs for cancer patients |
| Q89993252 | Personalized Approach to Cancer Treatment-Related Cardiomyopathy |
| Q35039202 | Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury |
| Q64245417 | Physiopathology and diagnosis of cardiotoxicity in patients submitted to chemotherapy treatment |
| Q92612178 | Position Statement on Indications of Echocardiography in Adults - 2019 |
| Q49037203 | Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors |
| Q91832458 | Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer |
| Q57113998 | Priorities in the Cardiovascular Care of Breast Cancer Survivors |
| Q59478893 | Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic |
| Q92302417 | Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019' |
| Q38237495 | Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway |
| Q48640610 | Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients. |
| Q39178080 | Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis |
| Q37648395 | Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer |
| Q36626934 | Roadmap for biomarkers of cancer therapy cardiotoxicity |
| Q55429574 | Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. |
| Q36416745 | Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines |
| Q34863501 | Role of echocardiography in the management of cardiac disease in women |
| Q35872865 | S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers |
| Q38896955 | SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. |
| Q41245359 | Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients |
| Q27007849 | Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients |
| Q52683313 | Sex differences in heart failure. |
| Q38982304 | Should the 'echo guidelines' be followed in cancer patients? |
| Q92776945 | Simultaneous Left Ventricular Volume and Strain Changes During Chemotherapy Associate With 2-Year Postchemotherapy Measures of Left Ventricular Ejection Fraction |
| Q38095634 | Speckle tracking echocardiography in pediatric and congenital heart disease |
| Q48585950 | Speckle tracking echocardiography predicts early subclinical anthracycline cardiotoxicity in patients with breast cancer |
| Q39962402 | Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. |
| Q48143732 | State of the art review: Chemotherapy-induced cardiotoxicity in children. |
| Q38734695 | Strain Imaging: The Emergence of Speckle Tracking Echocardiography into Clinical Pediatric Cardiology |
| Q38353651 | Strain, strain rate, torsion, and twist: echocardiographic evaluation |
| Q38551776 | Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers |
| Q90692278 | Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime? |
| Q64233611 | Subclinical Left Ventricular Dysfunction During Chemotherapy |
| Q57488040 | Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology |
| Q52989886 | Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Patients. |
| Q60914142 | Ten Years of 2D Longitudinal Strain for Early Myocardial Dysfunction Detection: A Clinical Overview |
| Q57787339 | The Assessment of Left Ventricle Function and Subclinical Atherosclerosis in Patients with Acute Myeloid Leukemia |
| Q46269647 | The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy. |
| Q97544688 | The Role of Biomarkers in Cardio-Oncology |
| Q26743433 | The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy |
| Q92980788 | The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics |
| Q61454606 | The breast cancer patient in the cardioncology unit |
| Q92582766 | The cardiotoxicity effect of different chemotherapeutic regimens in Iraqi patients with breast cancer: A follow up study |
| Q49984892 | The connection between the breast and heart in a woman: Breast cancer and cardiovascular disease. |
| Q47375125 | The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT. |
| Q97527718 | The effect of prophylactic carvedilol on subclinical left ventricular dysfunction after 1 cycle FAC chemotherapy in breast cancer patients |
| Q52777491 | The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults. |
| Q38662906 | The intriguing occurrence of Segmental Arterial Mediolysis; Case report and concise literature review |
| Q47567559 | The paradox of the first cycle of chemotherapy-transient improvement of contractility and diastolic function after the first cycle of anthracycline-based chemotherapy: a prospective clinical trial. |
| Q52982588 | The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. |
| Q100418466 | The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology |
| Q38982290 | The use of myocardial strain and newer echocardiography imaging techniques in cancer patients. |
| Q48325287 | Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy |
| Q57213890 | Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs |
| Q38097736 | Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively |
| Q36038613 | Trastuzumab Induces an Immediate, Transient Volume Increase in Humans: A Randomised Placebo-Controlled Trial |
| Q35047415 | Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice |
| Q37131070 | Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? |
| Q37145885 | Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer |
| Q33840140 | Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population |
| Q91464135 | Treatment exposures stratify need for echocardiographic screening in asymptomatic long-term survivors of hematopoietic stem cell transplantation |
| Q38734398 | Troponin in Cardiovascular Disease Prevention: Updates and Future Direction |
| Q91266299 | Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis |
| Q40872171 | Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer. |
| Q88779734 | Two-Dimensional Speckle Tracking Echocardiography-Derived Strain Measurements in Survivors of Childhood Cancer on Angiotensin Converting Enzyme Inhibition or Receptor Blockade |
| Q89184149 | Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity |
| Q38686222 | Update on cardiotoxicity of anti-cancer treatments |
| Q27027354 | Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity |
| Q39018351 | Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy |
| Q35905883 | Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. |
| Q35588736 | Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy |
| Q55405456 | What is the Role of Two-Dimensional Speckle Tracking Echocardiography in the Diagnosis and Management of Anthracycline-Induced Cardiotoxicity? |
| Q50418924 | [Current recommendations for diagnostic echocardiography in cancer patients : Is echocardiography too late or too early?] |